Alamar Biosciences (ALMR) Stock Price, News & Analysis
Company Description
Alamar Biosciences, Inc. develops proteomics technologies for protein detection and analysis. The company’s business centers on its NULISA technology, which stands for NUcleic Acid Linked Immuno-Sandwich Assay, and on a broader Precision Proteomics platform designed to detect and quantify protein biomarkers from small biofluid samples with high sensitivity and specificity.
Alamar sells instruments, consumables, and services based on its proteomic liquid biopsy platform. Its product portfolio includes NULISAseq panels, NULISAqpcr assays, and the ARGO HT fully automated, high-throughput system, which supports a sample-to-answer workflow. The company’s products are used in protein biomarker research, including applications tied to early disease detection and neurodegenerative disease research.
The company operates as a single-segment business focused on developing and commercializing protein-analysis tools. Its revenue model is tied to platform adoption, instrument sales, consumable usage, assay and panel offerings, and related services. Alamar’s customer base includes academic research institutions and biopharmaceutical organizations that use proteomics tools to study disease biology and biomarker signatures.
Alamar Biosciences is incorporated in Delaware and is headquartered in Fremont, California. Its common stock trades on the Nasdaq Stock Market under the symbol ALMR. The company completed its initial public offering in April 2026, after which it adopted amended and restated governing documents as a public company.
Stock Performance
Alamar Biosciences (ALMR) stock last closed at $24.71. At a market capitalization of $1.7B, ALMR is classified as a small-cap stock with approximately 69.3M shares outstanding.
ALMR Rankings
Latest News
Alamar Biosciences has 8 recent news articles, with the latest published yesterday. Of the recent coverage, 2 articles coincided with positive price movement and 4 with negative movement. Key topics include earnings date, partnership, earnings. View all ALMR news →
SEC Filings
Alamar Biosciences has filed 5 recent SEC filings, including 2 Form 8-K, 1 Form SCHEDULE 13D/A, 1 Form SCHEDULE 13G, 1 Form 10-Q. The most recent filing was submitted on July 15, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all ALMR SEC filings →
Financial Highlights
Upcoming Events
Q2 2026 Results
Earnings Conference Call
Alamar Biosciences has 2 upcoming scheduled events. The next event, "Q2 2026 Results", is scheduled for August 10, 2026 (in 11 days). Investors can track these dates to stay informed about potential catalysts that may affect the ALMR stock price.
Short Interest History
Short interest in Alamar Biosciences (ALMR) currently stands at 2.2 million shares, down 19.5% from the previous reporting period, representing 4.4% of the float. Since April 2026, short interest has increased by 94.8%. This relatively low short interest suggests limited bearish sentiment. The 7.6 days to cover indicates moderate liquidity for short covering.
Days to Cover History
Days to cover for Alamar Biosciences (ALMR) currently stands at 7.6 days, up 54.7% from the previous period. This moderate days-to-cover ratio suggests reasonable liquidity for short covering, requiring about a week of average trading volume. The days to cover has increased 412.2% over the past year, indicating either rising short interest or declining trading volume. The ratio has shown significant volatility over the period, ranging from 1.5 to 11.5 days.
ALMR Company Profile & Sector Positioning
Alamar Biosciences (ALMR) operates in the Medical Devices industry within the broader Laboratory Analytical Instruments sector and is listed on the NASDAQ. In monthly performance, the stock ranks #2,824 among all tracked companies.